The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid the rapid expansion of the global obesity treatment market, investors are pivoting toward a new wave of strategic acquisitions in the biotech sector. Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals in a deal valued at $10 billion. This move reinforces expectations that major pharmaceutical players are aggressively seeking advanced drug platforms to secure a foothold in the high-growth weight-loss market.
Speculation is mounting that Viking Therapeutics could be the next takeover target due to its promising obesity drug VK2735, as the sector is projected to reach $190 billion by 2035. Per market data, VRTX closed at $483.33 (close July 29, 2026), while VKTX stood at $33.86 (close July 28, 2026). This M&A activity highlights the trend of big pharma acquiring biotech firms with late-stage clinical assets to drive future growth.
Traders should monitor VKTX price levels, which saw a day low of $32.72 on July 28, 2026, as the market awaits critical Phase 3 data that could catalyze a formal bid. In the absence of immediate sector-specific economic calendar events, stock valuations will likely remain sensitive to clinical trial updates and further consolidation rumors in the pharmaceutical space.